Moderna (MRNA) stock fell on Friday after the struggling biotech company topped second-quarter forecasts but lowered full-year 2025 sales guidance.
Moderna reported a loss of $2.13 per share versus forecasts for losses of $2.96 a share. Revenue fell 41% to $142 million. Analysts polled by FactSet had projected a 53% drop to $112.5 million.
The biotech company lowered its full-year sales outlook by $300 million to a range of $1.5 billion to $2.2 billion, citing a delay in flu vaccine shipments.
Moderna plans to cut 10% of its workforce amid a falling cash balance. The company may need to raise capital, analysts say.
In early trades on the stock market today, Moderna stock fell 5% to near 28. Shares fell 8% on Thursday after the company disclosed job cuts in a letter to employees.
The biotech company has struggled as the Covid-19 vaccine market evaporates. It has lost billions of dollars annually since 2023.
Moderna stock has retreated 26% this year, and 78% over the past 12 months.
Follow Reinhardt Krause on X, formerly Twitter, @reinhardtk_tech for updates on artificial intelligence, cybersecurity and cloud computing.
YOU MAY ALSO LIKE:
Want To Trade Options? Try Out These Strategies
Monitor IBD's "Breaking Out Today" List For Companies Hitting New Buy Points
IBD Digital: Unlock IBD's Premium Stock Lists, Tools And Analysis Today
Build Custom Stock Screens With MarketSurge
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.